Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Treprostinil

Status:

Phase 2

Condition:

Sarcoidosis ILD

Intervention Type:

Inhaled Drug

Funder Type:

Organization | University

Drug Details

Inhaled treprostinil is an inhaled medication approved for the treatment of pulmonary arterial hypertension in World Health Organization (WHO) Group 1 patients. Inhaled treprostinil is a synthetic analogue of prostacyclin, a naturally occurring substance in the body, which has effects on dilating blood vessels. Inhaled treprostinil was approved for PAH by the United States Food and Drug Administration (FDA) in 2009, and PH-ILD in 2021.

Study Purpose

This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.

Find a Clinical Trial